🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Davide Melisi

University of Verona

ORCID: 0000-0002-4031-7585

Also affiliated with Azienda Ospedaliera Universitaria Integrata Verona

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial”.

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

The Lancet(2023)10.1016/s0140-6736(23)01366-1
N/A
5.4DataRank · unranked
454 citations

Davide Melisi, Teresa Macarulla, Roberto Pazo-Cid, Sreenivasa R Chandana, Christelle de la Fouchardière +14 more

Data from Anti-VEGF Treatment–Resistant Pancreatic Cancers Secrete Proinflammatory Factors That Contribute to Malignant Progression by Inducing an EMT Cell Phenotype

(2023)10.1158/1078-0432.c.6519875.v1
N/A
0DataRank · unranked
0 citations

Tania Moccia, Cihui Zhu, Genni Paradiso, Alfredo Budillon, Paul J. Chiao +3 more

Data from Anti-VEGF Treatment–Resistant Pancreatic Cancers Secrete Proinflammatory Factors That Contribute to Malignant Progression by Inducing an EMT Cell Phenotype

(2023)10.1158/1078-0432.c.6519875
N/A
0DataRank · unranked
0 citations

Tania Moccia, Cihui Zhu, Genni Paradiso, Alfredo Budillon, Paul J. Chiao +3 more